Early development evaluation of AZD8081: a substrate for the NK receptors

References

• Pennefather JN, Lecci A, Candenas ML, Patak E, Pinto FM, Maggi CA. (2004). Tachykinins and tachykinin receptors: a growing family. Life Sci, 74:1445–1463.
   PubMed Web of Science ®Google Scholar
• Quartara L, Altamura M. (2006). Tachykinin receptors antagonists: from research to clinic. Curr Drug Targets, 7:975–992.
   PubMed Web of Science ®Google Scholar
• Severini C, Improta G, Falconieri-Erspamer G, Salvadori S, Erspamer V. (2002). The tachykinin peptide family. Pharmacol Rev, 54:285–322.
   PubMed Web of Science ®Google Scholar
• Maggi CA, Patacchini R, Rovero P, Giachetti A. (1993). Tachykinin receptors and tachykinin receptor antagonists. J Auton Pharmacol, 13:23–93.
   PubMedGoogle Scholar
• Maggi CA. (1996). Tachykinins in the autonomic nervous system. Pharmacol Res, 33:161–170.
   PubMed Web of Science ®Google Scholar
• Stewart-Lee A, Burnstock G. (1989). Actions of tachykinins on the rabbit mesenteric artery: substance P and [Glp6,L-Pro9]SP6-11 are potent agonists for endothelial neurokinin-1 receptors. Br J Pharmacol, 97:1218–1224.
   PubMed Web of Science ®Google Scholar
• Tsuchida K, Shigemoto R, Yokota Y, Nakanishi S. (1990). Tissue distribution and quantitation of the mRNAs for three rat tachykinin receptors. Eur J Biochem, 193:751–757.
   PubMedGoogle Scholar
• Ho WZ, Lai JP, Zhu XH, Uvaydova M, Douglas SD. (1997). Human monocytes and macrophages express substance P and neurokinin-1 receptor. J Immunol, 159:5654–5660.
   PubMed Web of Science ®Google Scholar
• Lai JP, Douglas SD, Ho WZ. (1998). Human lymphocytes express substance P and its receptor. J Neuroimmunol, 86:80–86.
   PubMed Web of Science ®Google Scholar
• Patacchini R, Maggi CA. (2001). Peripheral tachykinin receptors as targets for new drugs. Eur J Pharmacol, 429:13–21.
   PubMed Web of Science ®Google Scholar
• Naline E, Devillier P, Drapeau G, Toty L, Bakdach H, Regoli D et al. (1989). Characterization of neurokinin effects and receptor selectivity in human isolated bronchi. Am Rev Respir Dis, 140:679–686.
   PubMed Web of Science ®Google Scholar
• Pennefather JN, Zeng XP, Gould D, Hall S, Burcher E. (1993). Mammalian tachykinins stimulate rat uterus by activating NK-2 receptors. Peptides, 14:169–174.
   PubMed Web of Science ®Google Scholar
• Croci T, Aureggi G, Manara L, Emonds-Alt X, Le Fuhr G, Maffrand JP, Mukenge S, Ferla G. (1998). In vitro characterization of tachykinin NK2-receptors modulating motor responses of human colonic muscle stripes. Br J Pharmacol, 124:1321–1327.
   PubMed Web of Science ®Google Scholar
• Saffroy M, Torrens Y, Glowinski J, Beaujouan JC. (2001). Presence of NK2 binding sites in the rat brain. J Neurochem, 79:985–996.
   PubMed Web of Science ®Google Scholar
• Saffroy M, Torrens Y, Glowinski J, Beaujouan JC. (2003). Autoradiographic distribution of tachykinin NK2 binding sites in the rat brain: comparison with NK1 and NK3 binding sites. Neuroscience, 116:761–773.
   PubMed Web of Science ®Google Scholar
• Massi M, Panocka I, de Caro G. (2000). The psychopharmacology of tachykinin NK-3 receptors in laboratory animals. Peptides, 21:1597–1609.
   PubMed Web of Science ®Google Scholar
• Page NM, Bell NJ. (2002). The human tachykinin NK1 (short form) and tachykinin NK4 receptor: a reappraisal. Eur J Pharmacol, 437:27–30.
   PubMed Web of Science ®Google Scholar
• Patak E, Candenas ML, Pennefather JN, Ziccone S, Lilley A, Martín JD et al. (2003). Tachykinins and tachykinin receptors in human uterus. Br J Pharmacol, 139:523–532.
   PubMed Web of Science ®Google Scholar
• Fioramonti J, Gaultier E, Toulouse M, Sanger GJ, Bueno L. (2003). Intestinal anti-nociceptive behaviour of NK3 receptor antagonism in conscious rats: evidence to support a pheripheral mechanism of action. Neurogastroenterology and Motility, 15:363–369.
   PubMed Web of Science ®Google Scholar
• Lecci A, Maggi CA. (2003). Peripheral tachykinin receptors as potential therapeutic targets in visceral diseases. Expert Opin Ther Targets, 7:343–362.
   PubMed Web of Science ®Google Scholar
• Kramer MS, Cutler N, Feighner J, Shrivastava R, Carman J, Sramek JJ et al. (1998). Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science, 281:1640–1645.
   PubMed Web of Science ®Google Scholar
• Leroy V, Mauser P, Gao Z, Peet NP. (2000). Neurokinin receptor antagonists. Expert Opin Investig Drugs, 9:735–746.
   PubMed Web of Science ®Google Scholar
• Holzer P, Holzer-Petsche U. (2001). Tachykinin receptors in the gut: physiological and pathological implications. Curr Opin Pharmacol, 1:583–590.
   PubMedGoogle Scholar
• Lecci A, Valenti C, Maggi CA. (2002). Tachykinin receptor antagonists in irritable bowel syndrome. Curr Opin Investig Drugs, 3:589–601.
   PubMedGoogle Scholar
• Wu Y, Loper A, Landis E, Hettrick L, Novak L, Lynn K et al. (2004). The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: a Beagle dog model predicts improved bioavailability and diminished food effect on absorption in human. Int J Pharm, 285:135–146.
   PubMed Web of Science ®Google Scholar
• Wan H, Holmén AG, Wang Y, Lindberg W, Englund M, Någård MB et al. (2003). High-throughput screening of pKa values of pharmaceuticals by pressure-assisted capillary electrophoresis and mass spectrometry. Rapid Commun Mass Spectrom, 17:2639–2648.
   PubMed Web of Science ®Google Scholar
• Tannergren C, Petri N, Knutson L, Hedeland M, Bondesson U, Lennernäs H. (2003). Multiple transport mechanism involved in the intestinal absorption and first-pass extraction of fexofenadine. Clinical Pharmacol Ther, 74:423–436.
   PubMed Web of Science ®Google Scholar
• Dressman JB, Amidon GL, Reppas C, Shah VP. (1998). Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. Pharm Res, 15:11–22.
   PubMed Web of Science ®Google Scholar
• Mortensen PB, Clausen MR, Bonnén H, Hove H, Holtug K. (1992). Colonic fermentation of ispaghula, wheat bran, glucose, and albumin to short-chain fatty acids and ammonia evaluated in vitro in 50 subjects. J Parenter Enteral Nutr, 16:433–439.
   PubMed Web of Science ®Google Scholar
• Nakahara Y, Kida T, Nakatsuji Y, Akashi M. (2005). New fluorescence method for the determination of the critical micelle concentration by photosensitive monoazacryptand derivatives. Langmuir, 21:6688–6695.
   PubMed Web of Science ®Google Scholar
• Amidon GL, Lennernäs H, Shah VP, Crison JR. (1995). A theoretical basis for a biopharmaceutic drg classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res, 12:413–420.
   PubMed Web of Science ®Google Scholar
• Lennernäs H, Abrahamsson B. (2005). The use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extension. J Pharm Pharmacol, 57:273–285.
   PubMed Web of Science ®Google Scholar
• Gupta E, Barends DM, Yamashita E, Lentz KA, Harmsze AM, Shah VP et al. (2006). Review of global regulations concerning biowaivers for immediate release solid oral dosage forms. Eur J Pharm Sci, 29:315–324.
   PubMed Web of Science ®Google Scholar
• Kortejärvi H, Urtti A, Yliperttula M. (2007). Pharmacokinetic simulation of biowaiver criteria: the effects of gastric emptying, dissolution, absorption and elimination rates. Eur J Pharm Sci, 30:155–166.
   PubMed Web of Science ®Google Scholar